

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 289603US0PCT		SERIAL NO. 10/577,064	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Kohei YAMADA, et al.			
				FILING DATE April 24, 2006		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
<i>PL</i>	AL	99 67378	12/29/1999	WO			NO
	AM	7 23395	3/15/1995	JP (equivalent of EP 0 219 829)			NO
	AN	2002 205996	7/23/2002	JP (equivalent of EP 1 178 051)			NO
<i>PL</i>	AO	63 258891	10/26/1988	JP (equivalent of EP 0 285 432)			NO
	AP						
	AQ						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
<i>PL</i>	AR	LOK et al., "POTENT GENE-SPECIFIC INHIBITORY PROPERTIES OF MIXED-BACKBONE ANTISENSE OLIGONUCLEOTIDES COMPRISED OF 2'-DEOXY-2'-FLUORO-D-ARABINOSE AND 2'-DEOXYRIBOSE NUCLEOTIDES", BIOCHEMISTRY, Vol. 41, pages 3457-3467, 2002					
	AS	MIN et al., "OLIGONUCLEOTIDES COMPRISED OF ALTERNATING 2'-DEOXY-2'-FLUORO-β-D-ARABINONUCLEOSIDES AND D-2'-DEOXYRIBONUCLEOSIDES (2'F-ANA/DNA 'ALTIMERS') INDUCE EFFICIENT RNA CLEAVAGE MEDIATED BY RNASE H", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, Vol. 12, pages 2651-2654, 2002					
	AT	TANN et al., "FLUOROCARBOHYDRATES IN SYNTHESIS. AN EFFICIENT SYNTHESIS OF 1-(2-DEOXY-2-FLUORO-β-D-ARABINO-FURANOSYL)-5-IODOURACIL (β-FIAU) AND 1-(2-DEOXY-2-FLUORO-β-D-ARABINOFURANOSYL)THYMINE (β-FMAU)", J. ORG. CHEM., Vol. 50, pages 3644-3647, 1985					
	AU	HOWELL et al., "ANTIVIRAL NUCLEOSIDES. A STEREOSPECIFIC, TOTAL SYNTHESIS OF 2'-FLUORO-2'-DEOXY-β-D-ARABINOFURANOSYL NUCLEOSIDES", J. ORG. CHEM., Vol. 53, pages 85-88, 1988					<input type="checkbox"/> Additional References sheet(s) attached
	AV	WILDS et al., "2'-DEOXY-2'-FLUORO-β-D-ARABINONUCLEOSIDES AND OLIGONUCLEOTIDES (2'F-ANA): SYNTHESIS AND PHYSICO-CHEMICAL STUDIES", NUCLEIC ACIDS RESEARCH, Vol. 28, No. 18, pages 3625-3635, 2000					
<i>PL</i>	AW	ELZAGHEID et al., "A NEW SYNTHESIS OF 9-(2-DEOXY-2-FLUORO-β-D-ARABINOFURANOSYL) GUANINE (ARAF-G)", NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, Vol. 22, No. 5-8, pages 1339-1342, 2003					
	AX	YAMADA et al., "PRACTICAL SYNTHESIS OF 2'-DEOXY-2'-FLUOROARABINOFURANOSYL PURINE NUCLEOSIDES BY CHEMO-ENZYMATIC METHOD", NUCLEIC ACIDS SYMPOSIUM SERIES, Vol. 48, pages 45-46, 2004					
Examiner					Date Considered		
					12-30-07		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 289603US0PCT		SERIAL NO. <b>U64</b> New U.S. PCT Application Based on PCT/JP04/15712	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Kohei YAMADA, et al.			
FILING DATE Herewith				GROUP			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES      NO		
<i>PL</i>	AO	2002-205996	7/23/2002	JP(English abstract only)		NO	
<i>PL</i>	AP	62-161797	7/17/1987	JP(equivalent of EP 0 219 829)		NO	
<i>PL</i>	AQ	03/057895	7/17/2003	WO(English abstract only)		NO	
	AR						
	AS						
	AT						
	AU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AW						
	AX						
	AY						
	AZ						<input type="checkbox"/> Additional References sheet(s) attached
Examiner <i>Michael L...</i>					Date Considered <i>12-30-07</i>		
<small>*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							